Evidence map›Paper›PMID 26475855›Full record

ArticleThe Journal of biological chemistry2015

Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis.

Masaki Inada, Morichika Takita, Satoshi Yokoyama, Kenta Watanabe, Tsukasa Tominari, Chiho Matsumoto, Michiko Hirata, Yoshiro Maru, Takayuki Maruyama, Yukihiko Sugimoto and 6 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Premetastasis.Cold Spring Harbor perspectives in medicine · 2020
    Review
  8. Review
  9. Article
  10. Review
  11. [Research progress of Candida albicans on malignant transformation of oral mucosal diseases].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2020
    Review
  12. Eicosanoids in Cancer: Prostaglandin EFrontiers in pharmacology · 2020
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. MgClExperimental and therapeutic medicine · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 2 countries.

Masaki InadaFrom the Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan, the Global Innovation Research Organization, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan.
Morichika TakitaFrom the Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan, the Department of Pharmacology, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
Satoshi YokoyamaFrom the Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan.
Kenta WatanabeFrom the Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan.
Tsukasa TominariFrom the Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan, the Global Innovation Research Organization, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan.
Chiho MatsumotoFrom the Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan.
Michiko HirataFrom the Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan.
Yoshiro Maruthe Department of Pharmacology, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
Takayuki Maruyamathe Minase Research Institutes, Ono Pharmaceutical Co. Ltd, Osaka 618-8585, Japan.
Yukihiko Sugimotothe Department of Pharmaceutical Biochemistry, Graduate School of Pharmaceutical Science, Kumamoto University, Kumamoto 862-0973, Japan.
Shuh Narumiyathe Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Satoshi Uematsuthe Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan, the Department of Mucosal Immunology, School of Medicine, Chiba University, Chiba 260-8670, Japan, the Division of Innate Immune, Regulation, International Research, and Development, Center for Mucosal Vaccines, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Shizuo Akirathe Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
Gillian Murphythe Global Innovation Research Organization, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan, the Department of Oncology, University of Cambridge, Cancer Research UK, Cambridge Institute, Li Ka Shing Centre, Cambridge CB2 0RE, United Kingdom, and.
Hideaki Nagasethe Global Innovation Research Organization, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan, the Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7FY, United Kingdom.
Chisato MiyauraFrom the Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan, the Global Innovation Research Organization, Tokyo University of Agriculture and Technology, 2-24-16 Nakamachi, Koganei, Tokyo 184-8588, Japan, miyaura@cc.tuat.ac.jp.
Tokyo University of Agriculture and Technology · JPChiba University · JPKumamoto University · JPKyoto University · JPOno Pharmaceutical (Japan) · JPOsaka University · JPTokyo Women's Medical University · JP

Funding

TIMP Engineering and Application to ArthritisR01AR040994 · NIAMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BREW, KEITH · 1991 to 2013
$4.8M
Arthritis Research UKCancer Research UKNIAMS NIH HHS AR40994NIAMS NIH HHS R01 AR040994
6 · The paper itself

Abstract

The stromal cells associated with tumors such as melanoma are significant determinants of tumor growth and metastasis. Using membrane-bound prostaglandin E synthase 1 (mPges1(-/-)) mice, we show that prostaglandin E2 (PGE2) production by host tissues is critical for B16 melanoma growth, angiogenesis, and metastasis to both bone and soft tissues. Concomitant studies in vitro showed that PGE2 production by fibroblasts is regulated by direct interaction with B16 cells. Autocrine activity of PGE2 further regulates the production of angiogenic factors by fibroblasts, which are key to the vascularization of both primary and metastatic tumor growth. Similarly, cell-cell interactions between B16 cells and host osteoblasts modulate mPGES-1 activity and PGE2 production by the osteoblasts. PGE2, in turn, acts to stimulate receptor activator of NF-κB ligand expression, leading to osteoclast differentiation and bone erosion. Using eicosanoid receptor antagonists, we show that PGE2 acts on osteoblasts and fibroblasts in the tumor microenvironment through the EP4 receptor. Metastatic tumor growth and vascularization in soft tissues was abrogated by an EP4 receptor antagonist. EP4-null Ptger4(-/-) mice do not support B16 melanoma growth. In vitro, an EP4 receptor antagonist modulated PGE2 effects on fibroblast production of angiogenic factors. Our data show that B16 melanoma cells directly influence host stromal cells to generate PGE2 signals governing neoangiogenesis and metastatic growth in bone via osteoclast erosive activity as well as angiogenesis in soft tissue tumors.

Indexed as

Cell DivisionNeoplasm MetastasisNeovascularization, PathologicSignal TransductionAnimalsDinoprostoneMelanoma, ExperimentalMiceMice, KnockoutReceptors, Prostaglandin E, EP4 SubtypeStromal CellsDinoprostoneReceptors, Prostaglandin E, EP4 SubtypeangiogenesisB16 melanomaboneBone resorptionEP4 receptorhost-cancer interactionmetastasisprostaglandinprostaglandin Etumor microenvironment

Identifiers

PMID26475855
PMCPMC4706013
OpenAlexW2193607076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.